

# UCSF

## UC San Francisco Previously Published Works

### Title

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy.

### Permalink

<https://escholarship.org/uc/item/82k034kh>

### Authors

Liu, Yamin

Vakrou, Styliani

Greenland, Gabriela

et al.

### Publication Date

2019

### DOI

10.3389/fcvm.2019.00170

Peer reviewed



# Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

Yamin Liu<sup>1,2</sup>, Junaid Afzal<sup>1,2</sup>, Styliani Vakrou<sup>2</sup>, Gabriela V. Greenland<sup>1,2</sup>, C. Conover Talbot Jr.<sup>3</sup>, Virginia B. Hebl<sup>4</sup>, Yufan Guan<sup>2</sup>, Rehan Karmali<sup>1</sup>, Jil C. Tardiff<sup>5</sup>, Leslie A. Leinwand<sup>6</sup>, Jeffrey E. Olgin<sup>1</sup>, Samarjit Das<sup>7</sup>, Ryuya Fukunaga<sup>8\*</sup> and M. Roselle Abraham<sup>1,2\*</sup>

<sup>1</sup> Division of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States, <sup>2</sup> Hypertrophic Cardiomyopathy Center of Excellence, Johns Hopkins University, Baltimore, MD, United States, <sup>3</sup> Johns Hopkins School of Medicine, Institute for Basic Biomedical Sciences, Baltimore, MD, United States, <sup>4</sup> Intermountain Medical Center, Intermountain Heart Institute, Murray, UT, United States, <sup>5</sup> Sarver Heart Center, University of Arizona Health Sciences, Tucson, AZ, United States, <sup>6</sup> Molecular, Cellular and Developmental Biology, Biofrontiers Institute, University of Colorado, Boulder, CO, United States, <sup>7</sup> Department of Anesthesia and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, United States, <sup>8</sup> Department of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, United States

## OPEN ACCESS

### Edited by:

Georges Nemer,  
American University of  
Beirut, Lebanon

### Reviewed by:

Alexander Maass,  
University Medical Center  
Groningen, Netherlands  
Henry J. Duff,  
University of Calgary, Canada

### \*Correspondence:

Ryuya Fukunaga  
fukunaga@jhmi.edu  
M. Roselle Abraham  
roselle.abraham@ucsf.edu

### Specialty section:

This article was submitted to  
Cardiovascular Genetics and Systems  
Medicine,  
a section of the journal  
Frontiers in Cardiovascular Medicine

Received: 06 June 2019

Accepted: 08 November 2019

Published: 17 December 2019

### Citation:

Liu Y, Afzal J, Vakrou S, Greenland GV, Talbot CC Jr, Hebl VB, Guan Y, Karmali R, Tardiff JC, Leinwand LA, Olgin JE, Das S, Fukunaga R and Abraham MR (2019) Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy. *Front. Cardiovasc. Med.* 6:170. doi: 10.3389/fcvm.2019.00170

**Background:** Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGF $\beta$  signaling only in TnT mutants. Dysregulation of miR-29 expression has been implicated in cardiac fibrosis. But it is unknown whether expression of miR-29a/b/c and profibrotic genes is commonly regulated in mouse and human HCM.

**Methods:** In order to understand mechanisms underlying fibrosis in HCM, and examine similarities/differences in expression of miR-29a/b/c and several profibrotic genes in mouse and human HCM, we performed parallel studies in rat cardiac myocyte/fibroblast cultures, examined gene expression in two mouse models of (*non-obstructive*) HCM (R92W-TnT, R403Q-MyHC)/controls at early (5 weeks) and established (24 weeks) disease stage, and analyzed publicly available mRNA/miRNA expression data from *obstructive*-HCM patients undergoing septal myectomy/controls (unused donor hearts).

**Results:** Myocyte cultures: ET1 increased superoxide/H<sub>2</sub>O<sub>2</sub>, stimulated TGF $\beta$  expression/secretion, and suppressed miR-29a expression in myocytes. The effect of ET1 on miR-29 and TGF $\beta$  expression/secretion was antagonized by N-acetyl-cysteine, a reactive oxygen species scavenger. Fibroblast cultures: ET1 had no effect on pro-fibrotic gene expression in fibroblasts. TGF $\beta$ 1/TGF $\beta$ 2 suppressed miR-29a and increased collagen expression, which was abolished by miR-29a overexpression. Mouse and human HCM: Expression of miR-29a/b/c was lower, and *TGFB1*/collagen gene expression was higher in TnT mutant-LV at 5 and 24 weeks; no difference was observed in expression of these genes in MyHC mutant-LV and in human myectomy tissue. *TGFB2* expression was higher in LV of both mutant mice and human myectomy tissue. *ACE2*, a negative regulator of the renin-angiotensin-aldosterone system, was the most upregulated

transcript in human myectomy tissue. Pathway analysis predicted upregulation of the anti-hypertrophic/anti-fibrotic liver X receptor/retinoid X receptor (LXR/RXR) pathway only in human myectomy tissue.

**Conclusions:** Our *in vitro* studies suggest that activation of ET1 signaling in cardiac myocytes increases reactive oxygen species and stimulates TGF $\beta$  secretion, which downregulates miR-29a and increases collagen in fibroblasts, thus contributing to fibrosis. Our gene expression studies in mouse and human HCM reveal allele-specific differences in miR-29 family/profibrotic gene expression in mouse HCM, and activation of anti-hypertrophic/anti-fibrotic genes and pathways in human HCM.

**Keywords:** hypertrophic cardiomyopathy, miR-29, TGF-beta, collagen, mouse, humans

## INTRODUCTION

Hypertrophic cardiomyopathy (HCM), most frequently caused by mutations in sarcomeric protein genes, manifests as myocyte hypertrophy, myocyte disarray, fibrosis, and arteriolar remodeling (1). Expression of the pathologic hallmarks of HCM vary with disease stage and underlying mutation. Our studies comparing two mouse models of HCM (R92W-TnT, R403Q-MyHC) with mutations in cardiac troponin T (cTnT) (2, 3) and myosin heavy chain (MyHC) genes (4, 5), at an early stage of disease (5 weeks of age), revealed differences in expression of *TGFBI3*, microRNA-29 (miR-29), collagen genes, and redox environment in the two mutant mouse lines (6). Dysregulation of cardiac miR-29 family (miR-29a/b/c) expression has been implicated in cardiac fibrosis in experimental models (7), and circulating miR-29a has been associated with cardiac fibrosis in HCM patients (8). But it is unknown whether miR-29 dysregulation varies with disease stage in HCM mouse models, and whether cardiac miR-29 expression is changed in human HCM (8). In order to address this question, we examined expression of *TGFBI3*, miR-29a/b/c, and collagen genes in the left ventricle (LV) and left atrium (LA) of TnT/MyHC mutants and littermate control mice at 5 and 24 weeks of age, and analyzed publicly available gene (mRNA, miRNA) expression data from human myectomy samples and control subjects.

In our recently published study, Ingenuity Pathway analysis (IPA) of gene (mRNA) expression data in 5 weeks old mouse hearts (R92W-TnT, R403Q-MyHC and littermate controls) predicted upregulation of endothelin1 (ET1) and transforming growth factor-beta signaling only in TnT mutants, that demonstrated an oxidized redox environment (6). Prior studies have demonstrated upregulation of TGF $\beta$  by mitochondrial reactive oxygen species (ROS) in lung fibroblasts (9), and by ET1 in cardiac myocytes (10). Additionally, ROS has been implicated as a mediator of ET1-induced cardiac hypertrophy (11, 12). We hypothesized that activation of ET1 signaling in cardiac myocytes increases ROS levels, which stimulates TGF $\beta$  secretion by cardiac myocytes, and collagen expression in cardiac fibroblasts. We tested this hypothesis by assessing miR-29 and select pro-fibrotic gene expression in (1) cardiac myocytes/fibroblasts following ET1 treatment, and (2) in cardiac fibroblasts following ET1, TGF $\beta$ 1, and TGF $\beta$ 2 treatment. Our

results indicate that ET1 increases ROS and stimulates TGF $\beta$  secretion by cardiac myocytes, which suppresses miR-29 and increases collagen expression in cardiac fibroblasts.

## MATERIALS AND METHODS


### Study Design

We performed studies in cardiac myocytes and cardiac fibroblasts derived from neonatal rat hearts, examined redox/gene expression in two mouse models of HCM/littermate controls at early and established disease stage, and analyzed publicly available gene expression data from HCM patients undergoing myectomy and controls, with a focus on TGF $\beta$ , miR-29 family, and its profibrotic target genes (Figure 1).

Studies in cardiac myocytes and fibroblasts obtained from healthy neonatal rat hearts were used to examine the effect of ET1 and redox modulation of cardiac myocytes on TGF $\beta$  signaling in cardiac myocytes, and collagen expression in cardiac fibroblasts. We examined miR-29a/b/c and profibrotic gene expression in the left ventricle (LV) and left atrial appendage (LA appendage) in 2 HCM mouse models because of the high incidence of cardiac fibrosis and ventricular/atrial arrhythmias in HCM patients. These two mouse models of sarcomeric HCM (R92W-TnT, R403Q-MyHC) are based on mutations that lead to sudden cardiac death at a young age in the setting of fibrosis/mild hypertrophy (13, 14), and significant LV hypertrophy/fibrosis/heart failure requiring heart transplantation in middle age (15, 16). Since obtaining endomyocardial biopsies from HCM patients for research is not feasible, we analyzed publicly available microarray datasets from HCM patients undergoing myectomy (compared to tissue obtained from unused donor hearts/controls) to assess whether expression of *TGFBI3*, miR-29a/b/c, and its profibrotic target genes is dysregulated in human HCM.

### Myocyte and Fibroblast Isolation From Neonatal Rat Hearts

Cardiac myocytes and cardiac fibroblasts were isolated from neonatal rat hearts as described previously (17). Briefly hearts from newborn Sprague Dawley rats (2–3 days old) were quickly excised, minced and digested with trypsin (at 4°C for 16–20 h) followed by collagenase type 2 (37°C for 30–45 min), following



which cell suspensions were centrifuged at  $100\times g$  for 5 min. The pellet was re-suspended in Dulbecco's Modified Eagle's Medium (DMEM) containing 4.5 g/L D-glucose, 10% fetal bovine serum (FBS), 100 U/mL penicillin/streptomycin (Pen/Strep), and transferred to a flask for 1 h for preferential attachment of fibroblasts. After 1 h, cardiac myocytes were plated in six well plates, at a density of  $6 \times 10^5$  per well. Fibroblasts adherent to the flask were cultured in DMEM containing 4.5 g/L D-glucose, 10% FBS, 100 U/mL Pen/Strep for the first 24 h. Fibroblasts were expanded in DMEM containing 1 gm/L D-glucose, 10% FBS, 100 U/mL Pen/Strep. Fibroblasts were allowed to proliferate until they were 70% confluent; fibroblasts were passaged twice prior to studies.

## Cell Treatment and miR-mimic Transfection Cardiac Myocytes

Neonatal rat cardiac myocytes were cultured in DMEM containing 4.5 g/L D-glucose, 10% FBS, 100 U/mL Pen/Strep for the first 24 h. Dead cells were removed by rinsing in PBS, and culture medium was changed to 45% DMEM (1 g/L D-glucose), 45% Medium 199, 10% FBS, 100 U/mL Pen/Strep for 24 h. Subsequently, cells were cultured in medium containing 49% DMEM (1 g/L D-glucose), 49% Medium 199, 2% FBS, 100 U/mL Pen/Strep for 12 h. On day 3 following initial plating, culture medium was changed to serum-free medium containing 50% DMEM (1 g/L D-glucose), 50% Medium 199, 100 U/mL Pen/Strep for 12 h prior to initiation of cell treatment with Endothelin1 (ET1) (11, 18, 19). We selected ET1 because it had the most pronounced effect on gene expression (ANP, BNP, TGFβ1-3, CTGF, and miR-29), when compared to Angiotensin II and Isoproterenol (data not shown).

Immunostaining was performed to confirm lack of fibroblast contamination of cardiac myocyte cultures

(**Supplemental Figure 1**). For immunostaining, cells were fixed with 3.7% paraformaldehyde for 15 min at room temperature, washed with PBS and incubated with blocking solution for 1 h. Vimentin antibody (1:200; cat. no. D21H3; Cell Signaling Technology, Inc., Danvers, MA, USA) was added overnight at  $4^{\circ}\text{C}$ , followed by secondary antibody [Alexa-488 goat anti-rabbit IgG (H + L), 1:2,000; Cat.#A32731, Thermo Fisher Scientific] for 1 h. Hoechst (1:2,000; cat. no. H3569; Thermo Fisher Scientific, USA) was used to label nuclei. Slides were imaged using a Nikon confocal microscope with 20X objective.

We studied the following conditions: (1) Control, (2) ET1 treatment (ET1; 100 nM; Sigma) (20), (3) ET1 + N-acetyl-l-cysteine (NAC, 3.5 mM; Sigma). ET1 and NAC were added for 24 h; cell viability was confirmed prior to cell harvesting for gene and protein expression studies.

## Cardiac Fibroblasts

Neonatal rat cardiac fibroblasts were expanded in DMEM containing 1 gm/L D-glucose, 10% FBS, 100 U/mL Pen/Strep. Fibroblasts were plated in six well-plates at a density of  $0.5 \times 10^6$  cells per well, and cultured in DMEM containing 10% FBS for 24 h. Medium was subsequently changed to DMEM containing 2% FBS for 24 h. Medium was changed to serum-free DMEM for 8 h prior to treatment with ET1/TGFβ/miR-mimic (21, 22).

The miR-29a-mimic (Cat.#4464066) and control mimic (Control-mimic; Cat.#4464058) were purchased from Life Technologies, Inc. For miR-29a overexpression studies, cardiac fibroblasts were transfected with miR-29a-mimic (5 nM) or control-mimic (5 nM) for 6 h using Lipofectamine<sup>®</sup> RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer instructions. Culture medium was changed to serum-free DMEM prior to treatment with TGFβ1 or TGFβ2.

We studied the following conditions: (1) Control, (2) TGF $\beta$ 1 (2 ng/mL; R&D Systems, Wiesbaden, Germany), (3) TGF $\beta$ 2 (1 ng/mL; R&D Systems, Wiesbaden, Germany), (4) TGF $\beta$ 1 + miR-29a-mimic, (5) TGF $\beta$ 1 + control-mimic, (6) TGF $\beta$ 2 + miR-29a-mimic; and (7) TGF $\beta$ 2 + control-mimic, for 24 h. Cell viability was confirmed by microscopy prior to harvesting for gene and protein expression studies.

## HCM Mouse Models

The investigation conforms to the “Guide for the Care and Use of Laboratory Animals” published by the US National Institutes of Health (NIH 8th Edition, 2011), and was approved and monitored by the UCSF Laboratory Animal Resource Center. We studied two mouse models of sarcomeric HCM that have been well-characterized, namely the R403Q mutation in the  $\alpha$ -myosin heavy chain gene (MyHC; *MYH6* gene) and the R92W mutation in the cardiac troponin T gene (TnT; *TNNT2* gene), that were kindly provided by Leinwand and Tardiff, respectively (3, 4). Mice were weaned and genotyped at the age of 4 weeks using PCR-amplified tail DNA. We studied male mice (mutants and littermate controls) at 5 and 24 weeks of age (redox studies, qPCR), and female mice at 5 weeks of age (qPCR of mouse LV tissue).

## Adult Mouse Myocyte Isolation

Adult cardiac myocytes were dissociated as described previously (6). Briefly, mice were administered 100 IU heparin 10 min prior to euthanasia by cervical dislocation. Hearts were rapidly excised, cannulated via the aorta, and perfused in the Langendorff mode with a constant perfusion pressure of 80 mmHg. Hearts were perfused for 10 min using Ca<sup>2+</sup>-free Tyrode containing (in mM) NaCl (120), KCl (5.4), NaH<sub>2</sub>PO<sub>4</sub> (1.2), NaHCO<sub>3</sub> (20), MgCl<sub>2</sub> (1.6), glucose (1 mg/ml), 2, 3-butanedione monoxime (BDM, 1 mg/ml), taurine (0.628 mg/ml), 0.9 mg/ml collagenase type 2 (Worthington, 299 U/mg), and gassed with 95% O<sub>2</sub>-5% CO<sub>2</sub>. The heart was then cut into small pieces and gently agitated, allowing myocytes to be dispersed in Ca<sup>2+</sup>-free Tyrode containing BSA (5 mg/L) for 10 min. Dispersed myocytes were filtered through a 150  $\mu$ M mesh and gently centrifuged at 500 rpm for 30 s. Myocytes were then suspended in Tyrode containing gradually increasing amounts of Ca<sup>2+</sup> (0.125–1 mM Ca<sup>2+</sup>) and stored in 1 mM Ca<sup>2+</sup>-containing Tyrode for microscopy studies.

## RNA Isolation and Polymerase Chain Reaction

Total RNA from mouse LV, left atrial (LA) appendage, rat cardiac myocyte cultures and rat cardiac fibroblast cultures was extracted using an RNA isolation Kit (Life Technologies) according to the manufacturer's instructions. RNA (1  $\mu$ g of each sample) was reverse-transcribed into cDNA using cDNA Reverse Transcription kit (Applied Biosystems).

## mRNA

Real-time RT-PCR for mRNA was performed using the TaqMan assay on a QuantStudio 7 Flex Real-Time PCR System (ThermoFisher, Inc.). Real-time RT-PCR was performed in

duplicate, and samples were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. We tested the following genes involved in cardiac fibrosis. Profibrotic targets of miR-29, identified by TargetScan: collagen genes (*COL1A1*, *COL1A2*, and *COL3A1*) and elastin (*ELN*); connective tissue growth factor (*CTGF*); transforming growth factor-beta isoforms (*TGFBI-3*); transforming growth factor-beta receptors (*TGFBR1-2*). Additionally, we assessed genes involved in ROS scavenging [superoxide dismutase2 (*SOD2*), catalase (*CAT*)] and modulators of cardiac fibrosis [atrial natriuretic peptide (*ANP*), brain natriuretic peptide (*BNP*)].

## miRNA

The real-time RT-PCR, TaqMan microRNA assay kit (Applied Biosystems) was used to quantify expression of mature miR-29a, miR-29b, and miR-29c in heart tissue, cardiac myocytes and cardiac fibroblasts. Real-time RT-PCR was performed in duplicate, and samples were normalized to U6 expression.

## Western Blot

Cardiac myocytes and fibroblasts were lysed in radio-immunoprecipitation assay lysis buffer (RIPA, Cat.#9806, Cell Signaling Technology) in the presence of protease inhibitors. Protein concentration was quantified using the bicinchoninic acid assay kit (Thermo Fisher Scientific). Denatured proteins (20  $\mu$ g) from the samples were run on 4–12% NuPAGE<sup>TM</sup> Bis-Tris Gel (Thermo Fisher Scientific), following which proteins were transferred to polyvinylidene difluoride membranes. The membranes were subsequently blocked using 5% BSA for 1 h at room temperature, and incubated with TGF $\beta$  (Cat.#3711; 1:2,000; Cell Signaling) or collagen I (Cat.#ab233080; 1:3,000; Abcam) primary antibody, overnight at 4°C, washed several times, and then incubated with GAPDH (Cat.#5174; 1:20,000; Cell Signaling Technology) for 1 h at room temperature. Subsequently, a horseradish peroxidase-linked anti-rabbit IgG secondary antibody (Cat. #NA9340; 1:20,000; GE healthcare, Inc.) was incubated for 1 h at room temperature. An enhanced chemi-luminescence reagent (SuperSignal<sup>TM</sup> West Femto Maximum Sensitivity Substrate; Thermo Fisher Scientific) was used to visualize the protein bands. Semi-quantification of protein was conducted by comparison against the GAPDH bands using Image J software (version 1.48, National Institutes of Health, Bethesda).

## Quantification of TGF $\beta$ 2 Secretion by ELISA

Release of TGF $\beta$ 2 protein from cardiac myocytes into serum-free culture medium was determined using the Quantikine colorimetric sandwich enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems), according to the manufacturer's instructions. ELISA was performed in duplicate. Absorbance at 450 nm was measured using a BioTek Synergy 2 multi-mode microplate reader. Protein concentration was calculated using a standard curve, and expressed as pg/10<sup>6</sup> cells.

## Measurement of Reactive Oxygen Species and Cellular Redox Status

### Rat Cardiac Myocyte Cultures

Neonatal rat cardiac myocytes were incubated with ET1 in the presence or absence of N-acetyl cysteine (NAC, 3.5 mM) for 24 h prior to imaging. Production of ROS in cultured cardiac myocytes was quantified using the cell-permeant fluorescence probes CM-H<sub>2</sub>DCFDA (DCF; Cat.#C6827, Thermo Fisher) and MitoSOX Red (Cat.#M36008), using an Olympus FV1000 MP microscope and 20X water immersion lens as described previously (23). Beating cardiac myocytes were incubated with DCF (5 μM) and MitoSOX Red (5 μM) for 30 min at 37°C, washed with PBS, prior to imaging at 37°C. We used an excitation wavelength of 800 nm. Emitted light was collected by three photomultiplier tubes fitted with bandpass filters. 512 × 512 pixel images were collected and image analysis was performed using Image J (NIH, <http://rsb.info.nih.gov/ij/>). Signal quantification was performed by drawing a region of interest (ROI) and calculating mean fluorescence intensity which was normalized to fluorescent area. DCF and Mitosox fluorescence was calculated from 10 randomly selected regions from three biological replicates (~300 cardiac myocytes).

### Isolated Mouse Cardiac Myocytes


Cellular redox status was examined in freshly isolated, non-paced, adult mouse cardiac myocytes, as described previously (6). Experiments were performed at 37°C in a thermostatically controlled flow chamber mounted on the stage of an upright

microscope (Nikon E600FN) attached to a multi-photon laser scanning system with excitation at 740 nm. Cells were suspended in Tyrode solution, pH 7.4, containing (in mM), NaCl (140), KCl (5), MgCl<sub>2</sub> (1), HEPES (10), CaCl<sub>2</sub> (1), and glucose (10). Monochlorobimane (MCB, 50 μM, blue λ<sub>em</sub> 480 ± 20 nm) was loaded for 20 min on the stage of the microscope at 37°C to monitor reduced glutathione (GSH). Autofluorescence of NAD(P)H, namely total fluorescence collected at <490 nm was monitored separately. The acquired signal was calibrated by the addition of KCN (1 mM) for maximum reduction of existing NAD(P)H, followed by the addition of FCCP (5 μM) for maximum oxidation of NAD(P)H. Image analysis was performed using Image J software.

### Analysis of Gene Expression Data From HCM Patients

Gene expression data from publicly available microarray datasets, GSE36961 (mRNA) and GSE36946 (miRNA) was downloaded from the NCBI GEO database, and analyzed for differential gene expression. The microarray datasets were obtained from ventricular septal tissue of HCM patients undergoing myectomy at the Mayo Clinic (Rochester, MN), and from age/sex-matched donor hearts (control subjects) from the Sydney Heart Bank (24, 25). Information on HCM patient genotype/phenotype and control subjects was obtained from the publicly available Master's Thesis by Hebl (24).

Briefly, the raw data underwent quality control analysis. A microarray batch effect was noted in the data and adjusted



for in the subsequent expression analysis. Data from 1 HCM patient that proved to be an outlier by principle component analysis, was excluded from further analysis. The fluorescence signal values were  $\log_2$  converted and quantile normalized.

## Statistical Analysis

All results are expressed as mean  $\pm$  S.D. unless otherwise noted. Two tailed Student's *t*-test was used to compare data from each mutant mouse to its respective littermate control, and to compare expression of select genes from human myectomy samples with control subjects. Experiments requiring comparison of  $\geq 3$  conditions were analyzed by ANOVA and Tukey's test. Graphs were generated using Graphpad Prism 7.04 software. For Ingenuity pathway analysis, mRNA data from 105 HCM patient samples was compared to 39 controls by ANOVA using the Partek Genomics Suite 7.0 platform. Differential expression was reported as fold change, and its statistical significance as *P*-value. Gene identifiers were updated to current HGNC/NCBI nomenclature. A *P* < 0.05 was considered statistically significant.

## RESULTS

### Gene Expression in Rat Cardiac Myocyte and Fibroblast Cultures

#### Cultured Rat Cardiac Fibroblasts Express Higher miR-29a Levels Than Cardiac Myocytes

The miR-29 family, consisting of miR-29a, miR-29b, and miR-29c has been demonstrated to play an important role in cardiac (7), pulmonary (26), and renal (27) fibrosis. We found that expression of miR-29a was 5-fold higher in

cultured rat cardiac fibroblasts when compared to cultured rat cardiac myocytes (**Figure 2A**). Furthermore, miR-29b and miR-29c expression was very low in rat cardiac myocytes when compared to miR-29a (data not shown), which led us to focus on miR-29a in our cell studies. Of note, low expression of miR-29b/c when compared to miR-29a, has been described previously in rat hearts (GEO: GSE62883, GSE56300).

### ET1 Increases ROS and Stimulates TGF $\beta$ Secretion by Cardiac Myocytes

Fibrosis is a common pathologic and imaging feature in HCM (15, 28). In our recent study of MyHC and TnT mutant mouse hearts, before the onset of myocyte hypertrophy/fibrosis, pathway analysis of mRNA-seq data predicted up-regulation of ET1 signaling in both mutants (6). Since mutant sarcomeric proteins are expressed only in cardiac myocytes (not cardiac fibroblasts), and fibroblasts are the main effectors of cardiac fibrosis, we hypothesized involvement of a paracrine mechanism, namely TGF $\beta$  secretion by myocytes, in generation of ET1-mediated collagen deposition/fibrosis. We performed studies separately in neonatal rat cardiac myocyte and fibroblast cultures to test our hypothesis.

Treatment of cardiac myocytes with ET1 (100 nM) induced upregulation of *TGFB1-3*, *CTGF*, and suppression of miR-29a (**Figure 2B** and **Table 1**), but did not change expression of redox genes, *SOD2* and *CAT* (**Table 1**). ET1 also increased TGF $\beta$  protein expression (**Figure 2C**) and stimulated TGF $\beta$  secretion by cardiac myocytes (**Figure 2D**).


Two photon microscopy demonstrated increase in superoxide and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) levels in cardiac myocytes

**TABLE 1** | Effects of ET1, ET1+NAC on gene expression in cardiac myocyte cultures.

Genes	ET1		ET1 + NAC	
	FC	<i>P</i> -value vs. con	FC	<i>P</i> -value vs. ET1
Natriuretic peptide A ( <i>ANP</i> )	4.1	0.01	2.4	0.02
Natriuretic peptide B ( <i>BNP</i> )	12.4	0.005	5.2	0.006
Transforming growth factor, beta 1 ( <i>TGFB1</i> )	1.5	0.004	0.9	0.006
Transforming growth factor, beta 2 ( <i>TGFB2</i> )	6.4	0.03	1.3	0.04
Transforming growth factor, beta 3 ( <i>TGFB3</i> )	4.3	0.0001	2.4	0.001
Transforming growth factor, beta receptor 1 ( <i>TGFB1R1</i> )	1.6	0.004	0.8	0.01
Transforming growth factor, beta receptor 2 ( <i>TGFB1R2</i> )	0.7	0.1	0.6	0.8
Connective tissue growth factor ( <i>CTGF</i> )	5.6	0.002	2.1	0.005
MicroRNA-29a (miR-29a)	0.6	0.01	1.7	0.006
Collagen type I alpha 1 chain ( <i>COL1A1</i> )	1.4	0.005	1.1	0.009
Collagen type I alpha 2 chain ( <i>COL1A2</i> )	1.7	0.0009	1.1	0.0008
Collagen type III alpha 1 chain ( <i>COL3A1</i> )	1.3	0.03	1.0	0.03
Elastin ( <i>ELN</i> )	1.4	0.03	0.6	0.004
Superoxide dismutase 2 ( <i>SOD2</i> )	0.9	0.9	0.8	0.3
Catalase ( <i>CAT</i> )	1.2	0.6	0.7	0.1

Expression of miR-29a, select pro-fibrotic and redox genes in cardiac myocytes, following treatment with ET1 (100 nM) and ET1+NAC (3.5 mM).

Data are expressed as linear fold change (FC) compared to control or ET1; *n* = 3 (biological replicates) for each condition; all experiments were repeated three times. One-way ANOVA and Tukey's test were used to compare ET1, ET1+NAC, and control.



following ET1 treatment (Figure 3A). Treatment with the ROS scavenger, N-acetyl-cysteine (NAC), a therapy predicted to be effective by IPA, only in 5 week-old TnT mutants (6), reduced cellular superoxide/H<sub>2</sub>O<sub>2</sub>, reduced expression of pro-fibrotic genes (*TGFB1-3*, *CTGF*, *COL1A1*, *COL1A2*, and *COL3A1*), and up-regulated miR-29a expression in cardiac myocytes (Figures 3B1–3 and Table 1). NAC also antagonized the ET1-induced increase in TGFβ expression (Figure 3C) and secretion by cardiac myocytes (Figure 3D).

### TGFβ-Induced Collagen Expression in Cardiac Fibroblasts Is Prevented by a miR-29a-mimic

Since fibroblasts are the main effectors of cardiac fibrosis, we investigated the effect of ET1 and TGFβ on cardiac fibroblasts. ET1 did not change expression of *TGFB1-3*, miR-29a or its pro-fibrotic target genes in cardiac fibroblasts (Supplemental Figures 2A–C). In contrast, treatment with TGFβ1 (2 ng/ml) or TGFβ2 (1 ng/ml) downregulated miR-29a, upregulated *CTGF* and miR-29 targets (*COL1A1*,



*COL1A2*, *COL3A1*, and *ELN*) in cardiac fibroblasts (Table 2, Figures 4A1,2, Supplemental Figures 3A,B). Notably, a miR-29a-mimic prevented upregulation of collagen genes (*COL1A1*, *COL1A2*, and *COL3A1*), elastin, and collagen expression in cardiac fibroblasts, following TGF $\beta$ 1 and TGF $\beta$ 2 treatment (Table 2, Figures 4A–C, Supplemental Figures 3A,B) highlighting the importance of miR-29a as a mediator of collagen deposition/fibrosis (27).

Taken together, our *in vitro* studies indicate that ET1 increases ROS and induces TGF $\beta$  secretion by cardiac myocytes, which downregulates miR-29a and de-represses its pro-fibrotic target genes in cardiac fibroblasts, leading to an increase in collagen expression in fibroblasts (Figure 4D).

## Redox Status in Mouse HCM

### Allele-Specific Differences in Cardiac Myocyte Redox Status in HCM Mice

Since cellular redox status influenced TGF $\beta$  secretion by cardiac myocytes in our *in vitro* studies, we investigated cellular redox status in cardiac myocytes isolated from mutant and littermate control mouse hearts at 5 and 24 weeks of age. We performed two photon microscopy to assess reduced glutathione (GSH) and the NAD(P)H pool in isolated cardiac myocytes (Figure 5). Myocytes were labeled with monochlorobimane (MCB) to measure reduced glutathione (GSH), and cellular autofluorescence was used as an indicator of NAD(P)H.

TnT mutant myocytes had evidence of an oxidized redox environment, characterized by lower GSH, and NAD(P)H pool levels, when compared to littermate controls, at 5 weeks of age (Figures 5A,B). In contrast, MyHC mutant myocytes demonstrated a reduced redox environment, characterized by higher GSH and NAD(P)H pool at 5 weeks of age (6)—(Figures 5A,B).

At 24 weeks of age, both mutants demonstrated an oxidized redox environment. TnT mutants showed markedly lower GSH levels and a trend toward lower NAD(P)H pool levels ( $p = 0.05$ ) when compared to littermate controls, whereas MyHC

mutants demonstrated lower GSH and NAD(P)H pool levels, when compared to littermate controls (Figures 5C,D).

Taken together, our results indicate allele-specific, and disease stage-specific changes in cellular redox status in the two HCM mouse models.

## Gene Expression in Mouse and Human HCM

### Allele-Specific Differences in Expression of miR-29a/b/c and Pro-fibrotic Genes in Left Ventricle of HCM Mice

We studied two mouse models of sarcomeric HCM with mutations that lead to cardiac phenotypes that span the spectrum of human HCM, namely malignant ventricular arrhythmias (R92W-TnT) (2, 3) and heart failure (R403Q- $\beta$ MyHC) (4, 5, 16). The R403Q mutation in the *human*  $\beta$ -myosin motor domain, influences myosin-ATPase activity and leads to LV hypertrophy, severe heart failure (requiring heart transplantation), and/or arrhythmias (5, 29). In contrast, the R92W mutation in cTnT confers increased Ca<sup>2+</sup> sensitivity to muscle fiber contraction, and predisposes to cardiac fibrosis and ventricular arrhythmias/sudden cardiac death in young individuals, in the absence of significant hypertrophy (30).


Our recent study comparing molecular phenotypes in 5 weeks old R92W-TnT and R403Q-MyHC mice with their respective littermate controls, demonstrated reduction in miR-29 expression only in mutant TnT whole hearts (6). However, it is unknown whether these differences are driven by gene expression in the LA and/or LV, and whether they persist later in disease course. In order to address these questions, we isolated the LV and LA appendage from each mouse heart, and assessed expression of *TGFBI-3*, miR-29a/b/c, and select target genes in these two chambers of mutant and littermate control mice at 5 and 24 weeks of age.

We observed upregulation of *TGFBI-3* and *CTGF* expression in the LV of both mutant mice at 5 and 24 weeks of age, but *TGFBI-3* gene expression was increased in TnT mutant-LV, but not MyHC mutant-LV, at both time points (Figures 6A,B

**TABLE 2 |** Effects of TGF $\beta$ 1, TGF $\beta$ 2 and miR-29a mimic on gene expression in cardiac fibroblast cultures.

Genes	TGF $\beta$ 1		TGF $\beta$ 1 + miR-29a mimic		TGF $\beta$ 1 + control mimic		TGF $\beta$ 2		TGF $\beta$ 2 + miR-29a mimic		TGF $\beta$ 2 + control mimic	
	FC	P vs. con	FC	P vs. TGF $\beta$ 1	FC	P vs. con	FC	P vs. con	FC	P vs. TGF $\beta$ 2	FC	P vs. con
<i>TGFBR1</i>	1.1	0.12	1.1	0.7	1.1	0.1	0.8	0.4	0.7	0.2	0.7	0.1
<i>TGFBR2</i>	1.1	0.3	1.0	0.3	1.2	0.2	0.8	0.2	0.6	0.3	0.7	0.07
<i>CTGF</i>	2.3	0.002	1.8	0.09	4.8	0.02	6.5	3.2E-05	2.2	0.002	4.1	0.01
miR-29a	0.4	0.02	NA	NA	0.4	0.02	0.5	0.03	NA	NA	0.5	0.006
<i>COL1A1</i>	1.6	0.01	0.1	0.004	1.9	0.003	2.4	0.01	0.2	0.005	2.8	0.003
<i>COL1A2</i>	2.0	0.03	0.2	0.01	2.1	0.001	1.7	0.01	0.1	0.0007	1.6	0.02
<i>COL3A1</i>	1.5	0.02	0.1	0.004	1.3	0.01	2.0	0.01	0.3	0.0007	2.0	0.009
<i>ELN</i>	1.9	0.01	0.3	0.003	3.2	0.02	2.6	0.01	0.1	0.01	3.0	0.01

Expression of miR-29a, select pro-fibrotic genes in cardiac fibroblasts, following treatment with TGF $\beta$ 1 (2 ng/mL) or TGF $\beta$ 2 (1 ng/mL) with/without miR-29a mimic. Data are expressed as linear fold change (FC);  $n = 3$  for each condition; all experiments were repeated 3 times. One-way ANOVA and Tukey's test were used to compare TGF $\beta$ 1/2, TGF $\beta$ 1/2 + miR29a-mimic, TGF $\beta$ 1/2 + control-mimic and control. TGFBR1, Transforming growth factor, beta receptor 1; TGFBR2, Transforming growth factor, beta receptor 2; CTGF, Connective tissue growth factor; miR-29a, microRNA 29a; COL1A1, Collagen type I alpha 1 chain; COL1A2, Collagen type I alpha 2 chain; ELN, Elastin.



and Table 3). Furthermore, miR-29a/b/c was downregulated, and its pro-fibrotic target genes (*COL1A1*, *Col1A2*, *COL3A1*, and *ELN*) were upregulated in TnT mutant-LV, but not MyHC mutant-LV at both time points (Figures 6A,B and Supplemental Figure 4).

### Gene Expression in Left Atrial Appendage of HCM Mice

We did not find a statistically significant difference in the expression of *TGFBI-3*, miR-29a/b/c or its target genes in LA appendages from TnT and MyHC mutants compared to respective littermate control mice at 5 and 24 weeks of age (Supplemental Figure 5).


### Human Data: Gene Expression in Septal Myectomy Tissue Compared to Donor Heart Tissue (Controls)

We analyzed publicly available microarray data for mRNAs (GSE36961) and miRNAs (GSE36946) from ventricular septal tissue, obtained at the time of surgical myectomy from HCM patients, and control subjects (24, 31). Donor heart tissue (LV free wall or LV side of the interventricular septum) from the Sydney Heart Bank (24) was used as controls. Age of HCM patients ranged from 9 to 78 years. Patients had a severe cardiac HCM phenotype, with maximum LV wall thickness of  $2.2 \pm$

0.7 cm, and LV gradients of  $71.5 \pm 47.4$  mmHg (24). Genotyping was performed in 100/107 HCM patients undergoing myectomy, revealing pathogenic variants in MYH7 ( $n = 17$ ), MYBPC3 ( $n = 24$ ), TNNT2 ( $n = 4$ ), TNNC1 ( $n = 1$ ), TPM1 ( $n = 2$ ), MYL2 ( $n = 3$ ), and MYH6 ( $n = 1$ ) (24); no causal mutation was identified in the remainder ( $n = 48$ ). Figure 7A illustrates the age and sex distribution of HCM patients and control subjects. We excluded 1 HCM patient based on the results of our principle component analysis (PCA), leading to inclusion of 105 patients/39 controls from the mRNA dataset, and 106 patients/20 controls from the miRNA datasets (Figure 7B) in our analysis.

### Expression of Genes Involved in Cardiac Fibrosis

Since fibrosis is a prominent feature in the hypertrophied interventricular septum, we examined several genes involved in cardiac fibrosis. *TGFB2* and *TGFB3* were significantly upregulated, and *TGFBR2* was downregulated in HCM, but there was no difference in expression of *CTGF*, *TGFBI*, miR-29a/b/c and its pro-fibrotic targets (collagen genes, elastin), in myectomy samples compared to donor heart tissue (Figures 8A,B). Next, we examined expression of renin-angiotensin-aldosterone system (RAAS) genes. The angiotensin converting enzyme 2 (*ACE2*) gene, a




negative regulator of RAAS (32) was the most upregulated transcript in the HCM patient dataset (Table 4). Other members of the RAAS system, namely renin-binding protein (*RENBP*), renin receptor mannose-6-phosphate/insulin-like growth factor 2 receptor (*IGF2R*), angiotensinogen (*AGT*) and angiotensin II receptor type 1 (*AGTR1*) were significantly downregulated (Table 4), suggesting activation of compensatory anti-hypertrophic/anti-fibrotic pathways in human obstructive HCM.

We observed lower expression of *SOD2* and higher expression of catalase in myectomy tissue when compared to donor heart tissue. Furthermore,  *$\alpha$ MYHC*, *SERCA2a*, and *GLUT1* were downregulated, and *ANP* was upregulated, compared to donor heart tissue (Figure 8A), confirming activation of the fetal gene program (33) in human obstructive HCM.

## Signaling Pathways

We used Ingenuity Pathway Analysis (IPA, Qiagen) to predict dysregulated signaling pathways and upstream transcriptional regulators using the mRNA dataset. The red and blue dots in the volcano plot reflect the gene values used for IPA (Figure 9A). We used a  $\log_2$  fold change cutoff of 2SD (standard deviations) up or down, which corresponds to a linear fold change of  $\sim 1.37$ , for IPA.

Pathway analysis predicted activation of the liver X receptor/retinoid X receptor (LXR/RXR) pathway ( $Z = 2.0$ ;  $P = 0.00006$ ; Figure 9B), and downregulation of pro-hypertrophic ET1 signaling ( $Z = -1.1$ ;  $P = 0.007$ ), TGF $\beta$  signaling ( $Z = -2.2$ ;  $P = 0.4$ ), and cardiac hypertrophy signaling ( $Z = -1.5$ ;  $P = 0.5$ ) in human HCM hearts compared to control hearts (data not shown).



### Upstream Transcriptional Regulators

We used IPA to predict transcription factors that were up-regulated and down-regulated in human myectomy tissue, when compared to donor heart tissue. Transcription factors involved in development (SOX2, NKX2-3, and DACH1), inflammation (ZFP36), metabolism (SIRT1, FOXA2), and fibrosis-suppression (SMAD7) were predicted to be upregulated ( $Z > 2$ ) in HCM patients, when compared to controls (Figure 9C). Transcription factors involved in development/immune response (STAT3), metabolism/mitochondrial function (CREB1), cellular stress response/fibrosis (NUPR1), and cellular response to hypoxia (HIF1) were predicted to be most downregulated ( $Z > -4$ )

in human myectomy samples, when compared to donor heart tissue (Figure 9C).


### DISCUSSION

In this study, we demonstrate marked differences in expression of pro-fibrotic genes/pathways in mouse and human HCM. Gene expression analysis revealed activation of anti-hypertrophic and antifibrotic genes/pathways selectively in human myectomy tissue, which is novel. Our results in cardiac myocytes and fibroblasts provide insights into mechanisms whereby hypertrophy induction in cardiac myocytes promotes collagen

**TABLE 3** | Gene expression in mutant mouse-LV compared to littermate control-LV at 5 and 24 weeks of age.


Genes	5 week male mice LV				24 week male mice LV			
	TnT		MyHC		TnT		MyHC	
	FC	P-value vs. con	FC	P-value vs. con	FC	P-value vs. con	FC	P-value vs. con
<i>ANP</i>	29	0.04	16.3	0.01	0.9	0.3	3.1	7.4E-05
<i>BNP</i>	6.2	1.1E-05	2.7	0.1	1.2	0.1	1.7	0.004
<i>TGFB1</i>	2.0	0.001	0.9	0.7	1.3	0.004	1.2	0.4
<i>TGFB2</i>	6.5	6.4E-08	2.2	0.04	3.1	9.6E-06	1.6	0.03
<i>TGFB3</i>	2.7	1.0E-05	1.9	0.1	1.6	0.002	1.3	0.01
<i>TGFBR1</i>	2.6	8.4E-05	0.9	0.8	1.3	0.04	1.3	0.07
<i>TGFBR2</i>	2.0	2.2E-06	1.0	0.9	1.4	0.06	0.9	0.2
<i>CTGF</i>	4.4	0.0004	5.2	0.001	1.6	0.0003	2.0	0.002
miR-29a	0.5	0.03	0.8	0.4	0.6	0.01	1.2	0.2
miR-29b	0.6	0.03	1.2	0.5	0.7	0.03	0.4	0.06
miR-29c	0.3	0.04	1.7	0.04	0.4	0.004	0.8	0.3
Pri-miR-29a	0.6	3.5E-05	1.1	0.7	0.8	0.03	0.9	0.4
<i>COL1A1</i>	5.5	0.0006	3.0	0.06	1.8	0.002	1.1	0.7
<i>COL1A2</i>	3.1	1E-05	1.5	0.2	1.6	0.004	1.0	0.9
<i>COL3A1</i>	5.5	0.0002	1.4	0.2	1.6	0.0002	0.8	0.5
<i>ELN</i>	4.2	4.1E-07	2.0	0.2	1.4	0.02	0.7	0.06
<i>SOD2</i>	1.3	0.06	0.7	0.06	0.9	0.4	0.8	0.1
<i>CAT</i>	1.4	0.2	1.0	0.7	1.0	0.8	0.8	0.9

Expression data for miR-29a/b/c, select profibrotic and redox genes in the LV of TnT and MyHC mutant mice and respective littermate controls at 5 and 24 weeks of age. Data are expressed as mean  $\pm$  S.D.;  $n = 5$  in each group. The 2-tailed unpaired Student's *t* test was used to compare TnT mutants and MyHC mutants with respective littermate controls. ANP, Natriuretic peptide A; BNP, Natriuretic peptide B; TGFB1, Transforming growth factor, beta 1; TGFB2, Transforming growth factor, beta 2; TGFB3, Transforming growth factor, beta 3; TGFBR1, Transforming growth factor, beta receptor 1; TGFBR2, Transforming growth factor, beta receptor 2; CTGF, Connective tissue growthfactor; miR-29a, microRNA-29a; COL1A1, Collagen type I alpha 1 chain; COL1A2, Collagen type I alpha 2 chain; ELN, Elastin.



expression in fibroblasts. We confirmed allele-specific differences in expression of *TGFB*, miR-29 family, and its profibrotic target genes at both early and established disease stage in two mouse models of sarcomeric HCM. Our studies

of redox and gene expression suggest that allele-specific differences in redox and signaling pathways could contribute to allele-specific differences in upregulation of profibrotic genes in mouse HCM.



**FIGURE 8 |** Gene expression in human ventricular septal tissue of HCM patients undergoing myectomy compared with control (healthy organ donor) hearts. **(A)** Summary of mRNA data (select pro-fibrotic and redox genes) from 105 HCM patients compared to data from 39 controls shows upregulation of *TGFB2* and *TGFB3* and downregulation of *TGFBR2*, *ELN*, *αMYHC*, *SERCA2a*, and *GLUT1* genes. **(B)** Summary of data for miR-29a/b/c from 106 HCM patients compared with data from 20 controls shows no difference in expression of miR-29a/b/c between HCM patients and controls. \* $P < 0.05$ .

## Human HCM

Hypertrophic cardiomyopathy is classified as non-obstructive, labile obstructive or obstructive, based on pressure gradients

obtained by Doppler-echocardiography, at the level of the LV outflow tract and mid-LV cavity. Non-obstructive HCM is characterized by peak gradient  $<30$  mm Hg at rest and stress,

**TABLE 4** | Expression of RAAS genes in human myectomy tissue from HCM patients compared with control (healthy donor) hearts.

Gene	FC	Adjusted P-value
Angiotensin converting enzyme 2 ( <i>ACE2</i> )	3.5	2.2E-24
Renin-binding protein ( <i>RENBP</i> )	1.1	5.7E-05
Insulin-like growth factor 2 receptor ( <i>IGF2R</i> )	0.8	1.1E-03
Angiotensinogen ( <i>AGT</i> )	0.8	1.2E-04
Angiotensin II receptor type 1 ( <i>AGTR1</i> )	0.8	2.0E-13
Angiotensin converting enzyme ( <i>ACE</i> )	1.0	0.09
Angiotensin II receptor type 2 ( <i>AGTR2</i> )	1.0	0.9
Angiotensin II receptor associated protein ( <i>AGTRAP</i> )	0.9	0.4
Renin ( <i>REN</i> )	0.9	0.9
Aldosterone synthase ( <i>CYP11B2</i> )	1.0	0.4
(Pro)renin receptor ( <i>ATP6AP2</i> )	0.9	0.7
Cathepsin D ( <i>CTSD</i> )	0.9	0.5
Chymase A ( <i>CMA1</i> )	0.9	0.5

labile-obstructive HCM by peak gradient <30 mm Hg at rest, ≥30 mm Hg with stress, and obstructive HCM with peak gradient ≥30 mm Hg at rest and stress (34). Symptomatic HCM patients with obstructive HCM are referred for myectomy to relieve LV obstruction.

The ventricular septum is usually the most hypertrophied region and is a frequent location for late gadolinium enhancement, reflecting replacement fibrosis, by cardiac magnetic resonance imaging (35). Septal myectomy samples often demonstrate both replacement and interstitial fibrosis (36) by histopathology. To our surprise, analysis of gene expression in the excised hypertrophied ventricular septum revealed no difference in expression of *CTGF*, *TGFBI*, miR-29a/b/c, and its pro-fibrotic target genes (collagen genes, elastin) between HCM patients and control subjects. Notably, IPA predicted downregulation of pro-fibrotic/pro-hypertrophic TGFβ/ET1 signaling and several RAAS genes, along with marked upregulation of the LXR/RXR pathway, which is anti-fibrotic, and anti-hypertrophic. These results suggest that other mechanisms such as ischemia (30), cell death, and inflammation could underlie the fibrosis observed in the hypertrophied ventricular septum in human HCM. Interestingly, we did not find differences in expression of RAAS genes, and IPA did not predict upregulation of the LXR/RXR pathway in HCM mouse models that lack LV outflow tract obstruction at early and late disease stage (data not shown). These results suggest that LXR/RXR pathway activation may be a compensatory response (37) to sustained LV obstruction, which is characteristic of obstructive HCM.

The liver X receptor (LXR) and retinoic acid receptor (RXR) are nuclear receptors that form obligate heterodimers and bind to LXR response elements (LXREs) in the nucleus (38). In the heart, LXR expression has been reported to be 10- to 15-fold higher in non-myocytes (fibroblasts, endothelial cells) when compared to

cardiac myocytes (39). RXR is involved in cardiac development and LXR has been implicated in the adaptive metabolic response to hypertrophic stress (40). Studies in mouse models reveal that LXR regulate cell survival through ROS inhibition, antagonize TGFβ-mediated collagen synthesis, promote angiogenesis, and suppress pro-inflammatory NFκB signaling, which are all cardio-protective (39, 41, 42). But very little is known about the role of LXR/RXR pathway in the genesis of the cardiac HCM phenotype.


## Differential Expression of TGF-Beta Isoforms

Fibrosis is frequent in HCM patients, and contributes to arrhythmias and heart failure (27, 43, 44). *TGFBI* was up-regulated in TnT mutant-LV and ET1-treated cardiac myocytes, but not in human myectomy tissue or MyHC mutant-LV. The TGF-beta isoform upregulated in both mouse and human HCM, as well as ET1-treated cardiac myocytes, was *TGFBI*. Differential expression of TGFβ isoforms has also been reported in DCM mice (45), but the mechanisms underlying differential regulation of *TGFBI* and *TGFBI2* genes, and the implications of these differences on HCM pathophysiology is unknown. Our *in vitro* studies of gene and collagen expression reveal that both TGFβ1 and TGFβ2 suppress miR-29a, de-repress its profibrotic target genes, and stimulate collagen expression in cardiac fibroblasts.

## Association Between miR-29 and Cardiac Remodeling

A previous study of 41 HCM patients revealed significant increases in plasma levels of miR-29a and a positive association with cardiac hypertrophy and fibrosis, assessed by cardiac magnetic resonance imaging (8). This result was surprising, because tissue fibrosis has been associated with suppression of miR-29 expression, which should have resulted in a negative association between miR-29 and cardiac fibrosis. These clinical results could be explained by a recent study that performed over-expression and knockdown of miR-29 family in cardiac myocytes (46). Sassi et al. found that increasing miR-29 family in cardiac myocytes led to cardiac hypertrophy, and inhibition or genetic deficiency of miR-29 family protected against cardiac hypertrophy and fibrosis in a mouse model of chronic cardiac pressure overload. The authors proposed that de-repression of Wnt signaling underlies the pro-hypertrophic and pro-fibrotic effects of increased levels of miR-29 family in cardiac myocytes (46).

In our study, miR-29 family expression was lower in TnT mutant-LV at 5 and 24 weeks of age, but no difference was observed in MyHC mutant-LV at these two time points. Interestingly, TnT mutant-LV mass has been reported to be lower than controls at both time points (47), which may contribute to lower cardiac miR-29 family levels. We found no difference in expression of miR-29a/b/c and its pro-fibrotic target genes in ventricular septal tissue obtained from patients with obstructive HCM undergoing myectomy for relief of LV outflow tract/mid-cavity obstruction. The discrepancy between



our result and the clinical plasma-miRNA study which reported a positive association between miR-29a and cardiac hypertrophy and fibrosis, may be due to differences in cardiac physiology. The mean value for the LV outflow tract gradient, which is used to determine presence of LV outflow tract obstruction, was  $18 \pm 21$  mmHg, suggesting that most of the patients in the clinical plasma-miRNA study had non-obstructive HCM (8). In contrast, the HCM patients in our study had obstructive HCM which results in chronic increase in left ventricular afterload. Interestingly, Sassi et al. reported dynamic regulation of miR-29 family expression following transverse aortic constriction (TAC), which increases left ventricular afterload (46). They found a prominent increase in cardiac myocyte expression of miR-29 in the first 48 h after TAC surgery, and downregulation thereafter, which could help explain our results in myectomy tissue. It is also possible that circulating miRNAs may not correlate with miRNA expression in tissues like the heart. Investigation of plasma miR-29 family levels in conjunction with gene expression studies in patients undergoing myectomy would be helpful to define the relationship between cardiac expression and plasma levels of the miR-29 family.

### Allele-Specific and Disease Stage-Specific Differences in miR-29a/b/c and Pro-fibrotic Gene Expression

We observed 5-fold higher levels of miR-29a in cultured rat cardiac fibroblasts, when compared to rat cardiac myocytes,

which is similar to the results from a previous study (7). In contrast, Sassi et al. found that miR-29 family levels were 6-fold lower in freshly isolated cardiac fibroblasts, when compared to cardiac myocytes (46), and increased with cell culture. A likely explanation for this difference is that long term culture of cardiac fibroblasts on stiff substrates like tissue culture plastic or glass coverslips activates them to myofibroblasts (48).

In our *in vitro* study that employed cultured rat cardiac fibroblasts and myocytes, the pro-hypertrophic cytokine ET1 increased superoxide and  $H_2O_2$  levels, suppressed miR-29a/b/c expression, and induced TGF $\beta$  secretion by cardiac myocytes. Interestingly, ET1 was predicted (by IPA) to be upregulated in *both* mutants at 5 weeks of age (6), but TGF $\beta$  signaling was predicted to be upregulated only in TnT mutants. Furthermore, miR-29a/b/c was suppressed only in TnT mutants who also demonstrated an oxidized redox environment at 5 weeks of age. In contrast, MyHC mutants exhibited a reduced redox environment and demonstrated similar miR-29 expression as littermate controls at 5 weeks of age. Based on our *in vitro* results of ET1 increasing cellular ROS levels and TGFBI-3 expression, we speculate that TnT mutants that demonstrate an oxidized redox environment are more susceptible to ET1-stimulated activation of TGF $\beta$  signaling, which suppresses miR-29 and leads to increase in collagen gene expression/cardiac fibrosis. Our hypothesis is supported by identification of the antioxidant NAC, as a potential therapy by IPA, in TnT mutants, but not MyHC mutants at 5 weeks of age (6).



In addition to TGF $\beta$  signaling, hedgehog, NF $\kappa$ B signaling, C-Myc, CCAAT/enhancer-binding protein- $\alpha$  (CEBPA), and ROS have been demonstrated to regulate miR-29 expression (49–51). Our study did not detect a difference in miR-29a/b/c expression between human myectomy tissue and donor heart tissue, which was used as controls. Based on results of a prior study of HCM patients which suggested that obstructive HCM is associated with greater oxidative stress than non-obstructive HCM (52), we expected higher myocardial miR-29 levels in human myectomy tissue (51). The mechanism underlying our result could be downregulation ( $Z > -3$ ) of CEBPA, an inducer of miR-29 expression, in human myectomy samples. We speculate that the net effect of oxidative stress, CEBPA downregulation and lack of activation of TGF $\beta$  signaling, could have resulted in no difference in miR-29 family/target gene expression between HCM patients and controls, observed in our study.

## LIMITATIONS

We focused on the miR-29/TGF $\beta$  signaling pathway, and did not investigate the LXR-RXR pathway in HCM mouse models or *in vitro*. We limited our proof-of-principle studies to two mouse models of HCM, in order to examine allele-specific and stage-specific differences in redox and gene expression. Studies in additional experimental models (53) would be helpful to ascertain whether HCM pathophysiology is gene-specific or mutation-specific. We used publicly available microarray data, and did not have access to human myectomy tissue to perform qPCR or Western blot for confirmation of IPA predictions. Since human myectomy tissue was obtained from the septum, gene expression in this region may not be representative of the whole heart. Furthermore, the contribution of cardiac myocytes, fibroblasts, and endothelial cells to differences in gene expression observed in human heart tissue could not be assessed because RNA was obtained from homogenized heart tissue, without cell dissociation. Lastly, we obtained genotype information for the myectomy population from the publicly available Master's Thesis by Hebl (24), but did not have access to genotype data from individual patients. Hence we were unable to examine associations between HCM patient genotype and gene expression, in this study.

## CONCLUSION

In summary, we found marked differences in expression of *TGFBI*, miR-29 family and its pro-fibrotic target genes in two mouse models of sarcomeric HCM, and between mouse and human HCM. Only human myectomy tissue demonstrated upregulation of antihypertrophic/antifibrotic genes/pathways. Allele-specific differences in myocyte redox status and signaling pathways could contribute to the observed differences in expression of miR-29 family/profibrotic genes in the 2 mouse models of HCM, and differences in cardiac physiology could underlie predicted activation of compensatory anti-fibrotic/anti-hypertrophic signaling/genes selectively in human HCM. Parallel studies in mouse and human HCM are needed to define HCM

pathophysiology and identify therapies that prevent/regress the cardiac HCM phenotype in humans.

## DATA AVAILABILITY STATEMENT

The datasets generated for this study can be found in the GSE36961 (mRNA) and GSE36946 (miRNA).

## ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by the investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH 8th Edition, 2011) and was approved and monitored by UCSF Laboratory Animal Resource Center.

## AUTHOR CONTRIBUTIONS

YL, MA, and RF were responsible for overall study design and data analysis. YL designed, performed, and analyzed rat and mouse studies. RF and CT analyzed microarray data. JA performed two-photon studies in rat myocytes, and contributed to rat myocyte/fibroblast study design. SV performed two photon microscopy studies in isolated mouse cardiac myocytes. YG performed mouse myocyte isolation. YG and GG maintained the mouse colonies and performed mouse genotyping. RK assisted with rat and mouse studies. JT and LL provided transgenic mouse breeders for colony establishment. YL, RF, CT, MA, SD, VH, LL, JT, and JO were involved in manuscript preparation. All authors reviewed and approved the manuscript.

## FUNDING

This work was funded by the Innovator Project Award (American Heart Association) and startup funds from the UCSF Division of Cardiology to MA. This work was also funded by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, through the FY17 PRMRP Discovery under Award No. W81XWH-17-PRMRP-DA. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

## ACKNOWLEDGMENTS

The authors would like to acknowledge the support of NIH R01 GM116841 and American Heart Association 15SDG23220028 to RF; NIH R01 GM29090 and HL117138 to LL; NIH R01 HL075619 and HL107046 to JT.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcvm.2019.00170/full#supplementary-material>

### Supplemental Figure 1 | Vimentin immunofluorescence microscopy.

Immunostaining for vimentin demonstrates no fibroblast contamination of neonatal rat cardiac myocyte cultures. **(A1–A3)** Representative microscopy images of a neonatal rat cardiac fibroblast culture shows co-localization of Hoechst and vimentin-labeling. **(B1–B3)** Representative microscopy images of a neonatal rat cardiac myocyte culture shows nuclear labeling with Hoechst (blue), but no vimentin-positive cells.

**Supplemental Figure 2 |** ET1 has no effect on miR-29a and pro-fibrotic gene expression in cultured neonatal rat cardiac fibroblasts. **(A–C)** Summary of gene expression of *TGFB2*, *CTGF*, collagen genes, and miR-29a show no difference in expression between untreated (control) and fibroblasts treated with ET1 (100 nM for 24 h) [CON, control; ET1, endothelin1 (100 nM) treatment for 24 h. Data are expressed as mean  $\pm$  S.D.;  $n = 3$  (biological replicates); all experiments were repeated three times. Two tailed Student's *t*-test was used to determine significance; n.s., non-significant].

**Supplemental Figure 3 |** TGF $\beta$ 1/2 stimulated collagen expression in neonatal rat cardiac fibroblast cultures is antagonized by miR-29-mimic. Cardiac fibroblasts were either treated with 5 nM concentration of either miR-29a-mimic or control-mimic for 6 h, prior to stimulation with TGF $\beta$ 1 or TGF $\beta$ 2 for 24 h. **(A)**

miR-29a-mimic suppressed TGF $\beta$ 1-stimulated expression of profibrotic miR-29 targets, but not *CTGF*, which is not a miR-29 target gene (linear fold change is presented). **(B)** miR-29a-mimic suppressed TGF $\beta$ 2-stimulated expression of profibrotic miR-29 targets, but not *CTGF* (linear fold change is presented) [data are expressed as mean  $\pm$  S.D.;  $n = 3$  (biological replicates) for each condition; all experiments were repeated three times. One-way ANOVA and Tukey's test were used to compare treatment conditions; \* $P < 0.05$ ].

**Supplemental Figure 4 |** Allele-specific differences in expression of miR-29a, *ANP*, *TGFB1/2*, *COL1A1* in LV of female HCM mice/littermate controls at 5 weeks of age. **(A–E)** Allele-specific differences in expression of *ANP*, *TGFB1/2*, miR-29a, and *COL1A1* in female TnT and MyHC mutant mouse -LV and littermate control-LV at 5 weeks of age (Control-T, TnT-littermate control; TnT, TnT-mutant; Control-M, MyHC-littermate control; MyHC, MyHC-mutant) (data are expressed as mean  $\pm$  S.D.;  $n = 6$  in each group. The two-tailed unpaired Student's *t*-test was used to compare TnT mutants and MyHC mutants with respective littermate controls; \* $P < 0.05$ ; n.s., non-significant).

**Supplemental Figure 5 |** Gene expression in left atrial appendage of HCM mice and littermate controls at 5 and 24 weeks of age. **(A,B)** No difference in expression of miR-29a/b/c, select pro-fibrotic and redox genes between left atrial appendage of mutant mice and littermate controls at 5 and 24 weeks of age (control-T, TnT-littermate control; TnT, TnT-mutant; Control-M, MyHC-littermate control; MyHC, MyHC-mutant) (data are expressed as mean  $\pm$  S.D.;  $n = 5$  for each group. The two-tailed unpaired Student's *t*-test was used to compare TnT mutants and MyHC mutants with respective littermate controls; n.s., non-significant).

## REFERENCES

- Maron BJ. Hypertrophic cardiomyopathy: a systematic review. *JAMA*. (2002) 287:1308–20. doi: 10.1001/jama.287.10.1308
- Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. *J Clin Invest*. (2003) 112:768–75. doi: 10.1172/JCI15967
- Ertz-Berger BR, He H, Dowell C, Factor SM, Haim TE, Nunez S, et al. Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice. *Proc Natl Acad Sci USA*. (2005) 102:18219–24. doi: 10.1073/pnas.0509181102
- Vikstrom KL, Factor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. *Mol Med*. (1996) 2:556–67. doi: 10.1007/BF03401640
- Nag S, Sommese RF, Ujfalusi Z, Combs A, Langer S, Sutton S, et al. Contractility parameters of human beta-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. *Sci Adv*. (2015) 1:e1500511. doi: 10.1126/sciadv.1500511
- Vakrou S, Fukunaga R, Foster DB, Sorensen L, Liu Y, Guan Y, et al. Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. *JCI Insight*. (2018) 3:1–21. doi: 10.1172/jci.insight.94493
- van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. *Proc Natl Acad Sci USA*. (2008) 105:13027–32. doi: 10.1073/pnas.0805038105
- Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. (2014) 63:920–7. doi: 10.1016/j.jacc.2013.09.041
- Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, et al. Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. *J Biol Chem*. (2013) 288:770–7. doi: 10.1074/jbc.M112.431973
- Shimojo N, Jesmin S, Zaedi S, Maeda S, Soma M, Aonuma K, et al. Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta 1 and phosphorylated JNK. *Am J Physiol Heart Circ Physiol*. (2006) 291:H835–45. doi: 10.1152/ajpheart.01365.2005
- Tanaka K, Honda M, Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. *J Am Coll Cardiol*. (2001). 37:676–85. doi: 10.1016/S0735-1097(00)01123-2
- Hirofani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. *Circulation*. (2002) 105:509–15. doi: 10.1161/hc0402.102863
- Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med*. (1995) 332:1058–64. doi: 10.1056/NEJM199504203321603
- Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. *Circulation*. (2001) 104:1380–4. doi: 10.1161/hc3701.095952
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell*. (1990) 62:999–1006. doi: 10.1016/0092-8674(90)90274-I
- Abraham MR, Bottomley PA, Dimaano VL, Pinheiro A, Steinberg A, Traill TA, et al. Creatine kinase adenosine triphosphate and phosphocreatine energy supply in a single kindred of patients with hypertrophic cardiomyopathy. *Am J Cardiol*. (2013) 112:861–6. doi: 10.1016/j.amjcard.2013.05.017
- Golden HB, Gollapudi D, Gerilechaoguetu F, Li J, Cristales RJ, Peng X, et al. Isolation of cardiac myocytes and fibroblasts from neonatal rat pups. *Methods Mol Biol*. (2012) 843:205–14. doi: 10.1007/978-1-61779-523-7\_20
- Lim JY, Park SJ, Hwang HY, Park EJ, Nam JH, Kim J, et al. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. *J Mol Cell Cardiol*. (2005) 39:627–36. doi: 10.1016/j.yjmcc.2005.06.016
- McCommis KS, Douglas DL, Krenz M, Baines CP. Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. *J Am Heart Assoc*. (2013) 2:e000355. doi: 10.1161/JAHA.113.000355
- Eble DM, Strait JB, Govindarajan G, Lou J, Byron KL, Samarel AM. Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. *Am J Physiol Heart Circ Physiol*. (2000) 278:H1695–707. doi: 10.1152/ajpheart.2000.278.5.H1695
- Lv T, Du Y, Cao N, Zhang S, Gong Y, Bai Y, et al. Proliferation in cardiac fibroblasts induced by beta1-adrenoceptor autoantibody and the underlying mechanisms. *Sci Rep*. (2016) 6:32430. doi: 10.1038/srep32430
- Wang Q, Oka T, Yamagami K, Lee JK, Akazawa H, Naito AT, et al. An EP4 receptor agonist inhibits cardiac fibrosis through activation of PKA signaling in hypertrophied heart. *Int Heart J*. (2017) 58:107–14. doi: 10.1536/ihj.16-200
- Afzal J, Chan A, Karakas MF, Woldemichael K, Vakrou S, Guan Y, et al. Cardiosphere-derived cells demonstrate metabolic flexibility that

- is influenced by adhesion status. *JACC Basic Transl Sci.* (2017) 2:543–60. doi: 10.1016/j.jacbts.2017.03.016
24. Hebl VB. *The messenger RNA and microRNA transcriptomes of hypertrophic cardiomyopathy* (dissertation/master's thesis). Rochester, MN, United States: Mayo Clinic, College of Medicine (2012).
  25. Dos Remedios CG, Lal SP, Li A, McNamara J, Keogh A, Macdonald PS, et al. The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart disease. *Biophys Rev.* (2017) 9:431–41. doi: 10.1007/s12551-017-0305-3
  26. Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, et al. MicroRNA mimicry blocks pulmonary fibrosis. *EMBO Mol Med.* (2014) 6:1347–56. doi: 10.15252/emmm.201303604
  27. Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. *J Am Soc Nephrol.* (2012) 23:252–65. doi: 10.1681/ASN.2011010055
  28. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu—Val mutation and a 403Arg—Gln mutation. *Circulation.* (1992) 86:345–52. doi: 10.1161/01.CIR.86.2.345
  29. Lowey S, Lesko LM, Rovner AS, Hodges AR, White SL, Low RB, et al. Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. *J Biol Chem.* (2008) 283:20579–89. doi: 10.1074/jbc.M800554200
  30. Lu DY, Yalcin H, Yalcin F, Zhao M, Sivalokanathan S, Valenta I, et al. Stress myocardial blood flow heterogeneity is a positron emission tomography biomarker of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. *Am J Cardiol.* (2018) 121:1081–9. doi: 10.1016/j.amjcard.2018.01.022
  31. Virginia BH, Bos JM, Oberg AL, Sun Z, Maleszewski JJ, Ogut O, et al. Transcriptome profiling of surgical myectomy tissue from patients with hypertrophic cardiomyopathy reveals marked overexpression of ACE2. *Circulation.* (2012) 126:A11099. Available online at: [https://www.ahajournals.org/doi/abs/10.1161/circ.126.suppl\\_21.A11099](https://www.ahajournals.org/doi/abs/10.1161/circ.126.suppl_21.A11099)
  32. Ocaranza MP, Jalil JE. Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling. *Int J Hypertens.* (2012) 2012:594361. doi: 10.1155/2012/594361
  33. Yamanaka K, Houben P, Bruns H, Schultze D, Hatano E, Schemmer P. A systematic review of pharmacological treatment options used to reduce ischemia reperfusion injury in rat liver transplantation. *PLoS ONE.* (2014) 10:e0122214. doi: 10.1371/journal.pone.0122214
  34. Bhattacharya M, Lu DY, Kudchadkar SM, Greenland GV, Lingamaneni P, Corona-Villalobos CP, et al. Identifying ventricular arrhythmias and their predictors by applying machine learning methods to electronic health records in patients with hypertrophic cardiomyopathy (HCM-VAR-risk model). *Am J Cardiol.* (2019) 123:1681–9. doi: 10.1016/j.amjcard.2019.02.022
  35. Corona-Villalobos CP, Sorensen LL, Pozios I, Chu L, Eng J, Abraham MR, et al. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography. *Int J Cardiovasc Imaging.* (2016) 32:945–54. doi: 10.1007/s10554-016-0858-4
  36. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. *Eur Heart J Cardiovasc Imaging.* (2015) 16:14–22. doi: 10.1093/ehjci/jeu182
  37. Ma Z, Deng C, Hu W, Zhou J, Fan C, Di S, et al. Liver X receptors and their agonists: targeting for cholesterol homeostasis and cardiovascular diseases. *Curr Issues Mol Biol.* (2017) 22:41–64. doi: 10.21775/cimb.022.041
  38. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T, et al. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. *J Biol Chem.* (2002) 277:1705–11. doi: 10.1074/jbc.M105711200
  39. Cannon MV, van Gilst WH, de Boer RA. Emerging role of liver X receptors in cardiac pathophysiology and heart failure. *Basic Res Cardiol.* (2016) 111:3. doi: 10.1007/s00395-015-0520-7
  40. Cannon MV, Sillje HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, et al. Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. *EMBO Mol Med.* (2015) 7:1229–43. doi: 10.15252/emmm.201404669
  41. Spillmann F, Van Linthout S, Miteva K, Lorenz M, Stangl V, Schultheiss HP, et al. LXR agonism improves TNF-alpha-induced endothelial dysfunction in the absence of its cholesterol-modulating effects. *Atherosclerosis.* (2014) 232:1–9. doi: 10.1016/j.atherosclerosis.2013.10.001
  42. Cannon MV, Yu H, Candido WM, Dokter MM, Lindstedt EL, Sillje HH, et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. *Eur J Heart Fail.* (2015) 17:273–82. doi: 10.1002/ehf.243
  43. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, et al. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. *Eur J Heart Fail.* (2006) 8:115–21. doi: 10.1016/j.ejheart.2005.07.012
  44. Hurtado-de-Mendoza D, Corona-Villalobos CP, Pozios I, Gonzales J, Soleimanifard Y, Sivalokanathan S, et al. Diffuse interstitial fibrosis assessed by cardiac magnetic resonance is associated with dispersion of ventricular repolarization in patients with hypertrophic cardiomyopathy. *J Arrhythm.* (2017) 33:201–7. doi: 10.1016/j.joa.2016.10.005
  45. Burke MA, Chang S, Wakimoto H, Gorham JM, Conner DA, Christodoulou DC, et al. Molecular profiling of dilated cardiomyopathy that progresses to heart failure. *JCI Insight.* (2016) 1:e86898. doi: 10.1172/jci.insight.86898
  46. Sassi Y, Avramopoulos P, Ramanujam D, Gruter L, Werfel S, Giosele S, et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. *Nat Commun.* (2017) 8:1614. doi: 10.1038/s41467-017-01737-4
  47. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. *J Clin Invest.* (1998) 101:2800–11. doi: 10.1172/JCI2389
  48. Jones C, Ehrlich HP. Fibroblast expression of alpha-smooth muscle actin, alpha2beta1 integrin and alphavbeta3 integrin: influence of surface rigidity. *Exp Mol Pathol.* (2011) 91:394–9. doi: 10.1016/j.yexmp.2011.04.007
  49. Ehyolzer M, Schmid S, Wilkens L, Mueller BU, Pabst T. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. *Br J Cancer.* (2010) 103:275–84. doi: 10.1038/sj.bjc.6605751
  50. Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB, et al. The role of miR-29b in cancer: regulation, function, and signaling. *Oncol Targets Ther.* (2015) 8:539–48. doi: 10.2147/OTT.S75899
  51. Heid J, Cencioni C, Ripa R, Baumgart M, Atlante S, Milano G, et al. Age-dependent increase of oxidative stress regulates microRNA-29 family preserving cardiac health. *Sci Rep.* (2017) 7:16839. doi: 10.1038/s41598-017-16829-w
  52. Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. *Pharmacol Rep.* (2009) 61:491–5. doi: 10.1016/S1734-1140(09)70091-X
  53. Maass A, Leinwand LA. Animal models of hypertrophic cardiomyopathy. *Curr Opin Cardiol.* (2000) 15:189–96. doi: 10.1097/00001573-200005000-00012

**Conflict of Interest:** LL is a stockholder and founder of MyoKardia, Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Liu, Afzal, Vakrou, Greenland, Talbot, Hebl, Guan, Karmali, Tardiff, Leinwand, Olgin, Das, Fukunaga and Abraham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.